Hematological changes during androgen deprivation therapy

Asian Journal of Andrology

Volumn 14, Issue 2, 2012, Pages 187-192

  Grossmann, Mathis ^a   Zajac, Jeffrey D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

androgen deprivation therapy (ADT); anemia; prostate cancer

Indexed keywords

ANDROGEN; ANTIANEMIC AGENT; CYANOCOBALAMIN; ERYTHROPOIETIN; FLUTAMIDE; FOLIC ACID; GONADORELIN AGONIST; GOSERELIN; IRON; PLACEBO; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANEMIA; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL MATURATION; ERYTHROCYTOSIS; ERYTHROPOIESIS; HEMATOCRIT; HUMAN; HYPOGONADISM; LEUKOCYTE; LYMPHOCYTE; METASTASIS; MORTALITY; NEUTROPHIL; NONHUMAN; ORCHIECTOMY; POLYCYTHEMIA; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOCYTE; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANEMIA; ERYTHROPOIESIS; HEMATOPOIESIS; HUMANS; INCIDENCE; MALE; PROSTATIC NEOPLASMS;

EID: 84858039570     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.102     Document Type: Review

References (68)

1. Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 2011; 40: 655-71.
2. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24. (Pubitemid 40490022)
3. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL et al. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 2011; 194: 301-6.
4. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 2010; 95: E456-63.
5. Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 2011; 74: 289-93.
6. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 2008; 29: 534-9.
7. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-54. (Pubitemid 46684481)
8. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44. (Pubitemid 41043794)
9. Crafts RC. Effects of hypophysectomy, castration, and testosterone propionate on hemopoiesis in the adult male rat. Endocrinology 1946; 39: 401-13.
10. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. J Endocrinol Invest 2009; 32: 704-16.
11. Vahlquist B. The cause of the sexual differences in erythrocyte hemoglobin and serum iron levels in human adults. Blood 1950; 5: 874-5.
12. Verma S, Lewis D, Warne G, Grossmann M. An X-traordinary stroke. Lancet 2011; 377: 1288.
13. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-7. (Pubitemid 32269134)
14. Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF et al. Anemia, testosterone, and pituitary adenoma in men. J Neurosurg 2003; 98: 974-7. (Pubitemid 36460887)
15. Grossmann M, Panagiotopolous S, Sharpe K, MacIsaac RJ, Clarke S et al. Low testosterone and anaemia in men with type 2 diabetes. Clin Endocrinol (Oxf) 2009; 70: 547-53.
16. Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, GhanimHet al. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 2006; 29: 2289-94.
17. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93: 1834-40. (Pubitemid 351656526)
18. Grossmann M, Gianatti EJ, Zajac JD. Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 247-56.
19. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59.
20. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011; 96: 2341-53.
21. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006; 166: 1380-8. (Pubitemid 44036350)
22. Yeap BB, Beilin J, Shi Z, Knuiman MW, Olynyk JK et al. Serum testosterone levels correlate with haemoglobin in middle-aged and older men. Intern Med J 2009; 39: 532-8.
23. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008; 93: 914-9. (Pubitemid 351398573)
24. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ et al. Adverse events associated with testosterone replacement in middle-aged and oldermen: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451-7. (Pubitemid 41798454)
25. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.
26. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997; 96: 168-73.
27. Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ et al. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol 2010; 162: 385-90.
28. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010; 95: 1533-43.
29. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
30. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metab 2010; 95: 639-50.
31. Grossmann M. Diagnosis and treatment of hypogonadism in older men: proceed with caution. Asian J Androl 2010; 12: 783-6.
32. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72-80.
33. Moriyama Y, Fisher JW. Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures. Blood 1975; 45: 665-70.
34. Bachman E, Feng R, Travison T, Li M, Olbina G et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab 2010; 95: 4743-7.
35. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17: 29-33.
36. Maggio M, Blackford A, Taub D, Carducci M, Ble A et al. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 2006; 27: 725-8. (Pubitemid 44846010)
37. Rochira V, Zirilli L, Madeo B, Maffei L, Carani C. Testosterone action on erythropoiesis does not require its aromatization to estrogen: insights from the testosterone and estrogen treatment of two aromatase-deficient men. J Steroid Biochem Mol Biol 2009; 113: 189-94.
38. Hamilton JB. Role of testicular secretions as indicated by effects of castration in man and by studies of pathological conditions and short lifespan associated with maleness. Recent Prog Horm Res 1948; 3: 257-89.
39. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol 1998; 59: 230-3. (Pubitemid 28485504)
40. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42. (Pubitemid 28457865)
41. Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996; 29: 243-8. (Pubitemid 26365290)
42. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79: 933-41. (Pubitemid 28316762)
43. Choo R, Chander S, Danjoux C, Morton G, Pearce A et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol 2005; 12: 2547-52.
44. Joly F, Alibhai SM, Galica J, Park A, Yi QL et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006; 176: 2443-7. (Pubitemid 44665959)
45. Beer TM, Tangen CM, Bland LB, Hussain M, GoldmanBHet al. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006; 107: 489-96. (Pubitemid 44107208)
46. Ornstein DK, Beiser JA, Andriole GL. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999; 83: 43-6. (Pubitemid 29151405)
47. Curtis KK, Adam TJ, Chen SC, Pruthi RK, Gornet MK. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male 2008; 11: 157-61.
48. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377-83.
49. Ludwig H, van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-306. (Pubitemid 39348881)
50. Caro JJ, Salas M,Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21. (Pubitemid 32552805)
51. D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D et al. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer 2002; 95: 275-80. (Pubitemid 34787592)
52. Makipour S, Kanapuru B, Ershler WB. Unexplained anemia in the elderly. Semin Hematol 2008; 45: 250-4.
53. Voegeli TA, Kurtz A, Grimm MO, Effert P, Eckardt KU. Anemia under androgen deprivation: influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system. Horm Metab Res 2005; 37: 89-93. (Pubitemid 40445129)
54. Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 1991; 36: 190-4.
55. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-WahnefriedWet al. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005; 18: 421-30. (Pubitemid 40395362)
56. Foresta C, Mioni R, Bordon P, Gottardello F, Nogara A et al. Erythropoietin and testicular steroidogenesis: the role of second messengers. Eur J Endocrinol 1995; 132: 103-8.
57. Aapro M, Spivak JL. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 2009; 14(Suppl 1): 6-15.
58. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-24. (Pubitemid 351397066)
59. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-15.
60. Smith RE Jr, Aapro MS, Ludwig H, Pinter T, SmakalMet al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1040-50.
61. van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O et al. Risk of thromboembolic diseases in men with prostate cancer: results from the populationbased PCBaSe Sweden. Lancet Oncol 2010; 11: 450-8.
62. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000; 89: 2570-6. (Pubitemid 32011601)
63. Chuang KH, Altuwaijri S, Li G, Lai JJ, Chu CY et al. Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor. J Exp Med 2009; 206: 1181-99.
64. Olsen NJ, Gu X, Kovacs WJ. Bone marrow stromal cells mediate androgenic suppression of B lymphocyte development. J Clin Invest 2001; 108: 1697-704. (Pubitemid 33144879)
65. Erben RG, Eberle J, Stangassinger M. B lymphopoiesis is upregulated after orchiectomy and is correlated with estradiol but not testosterone serum levels in aged male rats. Horm Metab Res 2001; 33: 491-8. (Pubitemid 32881897)
66. Olsen NJ, Olson G, Viselli SM, Gu X, Kovacs WJ. Androgen receptors in thymic epithelium modulate thymus size and thymocyte development. Endocrinology 2001; 142: 1278-83. (Pubitemid 32202839)
67. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95: 2289-96. (Pubitemid 30167727)
68. Urhausen A, Torsten A, Wilfried K. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J Steroid Biochem Mol Biol 2003; 84: 369-75. (Pubitemid 36514853)